scholarly journals Palmoplantar Malignant Melanoma in the Brazzaville University Hospital

2017 ◽  
Vol 4 (1) ◽  
Author(s):  
Nsondé Malanda J ◽  
Kimpamboudi AVM ◽  
Soussa RB ◽  
Nkoua Mbon JB ◽  
Gombé Mbalawa Ch
Keyword(s):  
Malignant Melanoma ◽  
University Hospital

scholarly journals Primitive Anorectal Malignant Melanoma: A Rare And Aggressive Localization A Case Report

2020 ◽  
Vol 7 (07) ◽  
pp. 4871-4874
Author(s):  
Amal Hajri ◽  
Abdessamad El Azhary ◽  
Driss Erguibi ◽  
Rachid Boufettal ◽  
Saad Rifki El Jai ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Case Report ◽  
Malignant Melanoma ◽  
Rare Condition ◽  
University Hospital ◽  
Anorectal Melanoma ◽  
Review Of The Literature ◽  
The Third ◽  
Anorectal Malignant Melanoma ◽  
Digestive Cancers

Primary anorectal malignant melanoma is an extremely rare condition. It appears at the third highest frequency after melanomas of the skin and retina. Its prognosis is dreadful because of the early onset of metastases. The treatment remains essentially surgical. We report an observation of primitive anorectal melanoma, collected at the department of surgery for digestive cancers and liver transplantation of the Ibn Rochd University Hospital of Casablanca, with a review of the literature. In order to analyse the clinical, paraclinical and therapeutic characteristics of primary anorectal melanoma.

scholarly journals Activity of Skin Cancer Clinic at Martin University Hospital in 2017

2018 ◽  
Vol 18 (1) ◽  
pp. 21-29
Author(s):  
E Minarikova ◽  
M Smolarova ◽  
M Minarik
Keyword(s):  
Skin Cancer ◽  
Malignant Melanoma ◽  
Skin Lesions ◽  
Common Type ◽  
Upper Extremities ◽  
Breslow Thickness ◽  
University Hospital ◽  
Superficial Spreading ◽  
The University ◽  
Cancer Clinic

Abstract The authors present new cases of malignant melanoma seen at the Skin Cancer Clinic of the University Hospital in Martin in the year 2017. There have been 112 new cases of malignant melanoma, 66 in men and 46 in women, diagnosed in 2017. We have recorded a occurence of two melanomas in one person in 3 patients, two men and one women. One patient had metastatic melanoma found in lymph nodes without corresponding skin lesions. The most common tumor body localisation in both men and women was on the back (51 melanomas, 45 %). In women, the most common localisation was upper extremities (13 melanomas, 29 %), followed by lower extremities and the back at the same rate (11 melanomas, 24 %). In men, the most common localisation was on the back (40 melanomas, 60 %). Histologically, the most common type was superficial spreading malignant melanoma (50 melanomas), the second most common was non specific type of malignant melanoma (19 melanomas). The majority of cases were low risk lesions with histological Breslow thickness in the range from 0,1 mm to 1 mm (47 melanomas). High risk lesions with histological Breslow thickness more than 4 mm were the second most common type (24 melanomas).

scholarly journals High regional mortality due to malignant melanoma in Eastern Finland may be explained by the increase in aggressive melanoma types

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ville Suhonen ◽  
Jaana Rummukainen ◽  
Hanna Siiskonen ◽  
Arto Mannermaa ◽  
Ilkka T. Harvima
Keyword(s):  
Malignant Melanoma ◽  
University Hospital ◽  
Skin Cancer Prevention ◽  
Superficial Spreading ◽  
Dysplastic Nevus ◽  
Melanoma In Situ ◽  
High Age ◽  
Cancer Prevention Program ◽  
Eastern Finland

Abstract Background A regional skin cancer prevention program in Eastern Finland revealed a relatively high age-standardized mortality due to malignant melanoma during 2013–2017. An explanation for this is needed. Purpose To analyse the 543 melanoma samples in 524 subjects collected during 2000–2013 at Kuopio University Hospital and reposited in the Biobank of Eastern Finland. A focus was directed to factors related to metastasis. Methods The samples were analysed anonymously by examining the histopathological report, referral text and the list of diagnoses. A possible state of immunosuppression was evaluated. Results The mean age at the diagnosis of malignant melanoma (MM), lentigo maligna (LM) and melanoma in situ was relatively high, i.e., 66.2, 72.1 and 63.3, respectively. Especially the MM type increased markedly during 2000–2013. In further analyses of a representative cohort of 337 samples, the proportion of nodular melanoma and LM/LMM melanoma was relatively high, 35.6 and 22.0%, respectively, but that from superficial spreading melanoma relatively low (33.8%). Metastasis correlated with immunosuppression, male gender, Clark level, Breslow thickness, ulceration, mitosis count, invasion into vessels and/or perineural area, microsatellites, melanoma subtype, body site, recidivism, and the absence of dysplastic nevus cells. Conclusion The marked increase in aggressive melanomas with associated metastasis, and the relatively high age at diagnosis, can partially explain the mortality.

A statistical study on malignant melanoma over the past 12 years in Fukui University Hospital

2014 ◽  
Vol 20 (1) ◽  
pp. 182-187
Author(s):  
Masato Yasuta ◽  
Suguru Sato ◽  
Sachio Kouraba ◽  
Shiro Iino ◽  
Takahiro Kiyohara
Keyword(s):  
Malignant Melanoma ◽  
Statistical Study ◽  
University Hospital ◽  
The Past

scholarly journals Challenges and Variables Affecting the Success of Sentinel Lymph Node Biospy in Malignant Melanoma a 4-Year Analysis of Clinical Results

2013 ◽  
Vol 6 (2) ◽  
pp. 112-117
Author(s):  
Dobromir D. Dimitrov ◽  
Veselin I. Kirov ◽  
Borislav A. Ignatov ◽  
Boris D. Tsankov ◽  
Hyuliya E. Feradova ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Malignant Melanoma ◽  
Locally Advanced ◽  
Clinical Results ◽  
Lymph Node Biopsy ◽  
University Hospital ◽  
Blue Dye ◽  
Index Card ◽  
Success Ratio

Summary In the last 15 years, sentinel lymph node biopsy (SLNB) for patients with malignant melanoma (MM) has been introduced into the clinical practice. Our aim was to make a retrospective analysis of clinical results in order to assess the success ratio of SLNB and the variables affecting it in MM patients, treated in the Oncology Center at the University Hospital “Dr George Stranski” - Pleven, Bulgaria for a 4-year period. A research index card was used to process the oncologic files of 82 out of 102 patients with MM, treated and monitored at the Oncology centre between 01.01.2008 and 31.12.2011. TNM-stages, Breslow and Clark levels, location, characteristics of the skin lesion, diagnostic excision, type of lymph node dissection, number of SLN, localization of SLN, etc. were registered in the index card. SLNB staging was carried out in 28 patients. Sentinel lymph nodes were found in 22 of them. The success ratio of the method was 78.6%. Histologically, metastatic SLN were found in 4 cases. The Patent Blue Dye method was used in 22 of the cases (78%). A combined radiocolloid and dye method was used in 5 cases (18%). A radiocolloid method was used in 1 case (4%) only. Our research showed that more therapeutic lymph node dissections were performed in cases of locally advanced MM, which in turn worsened the clinical results. According to our research, the SLNB success ratio depends on the precision of diagnostic excision (p=0.019), lesion location (p=0.015), Clark level (p=0.0229), mapping method (p=0.08) and the type of melanoma (p=0.088).

scholarly journals SAT0578 RHEUMAL REGISTRY PROVIDES FIRST INSIGHTS INTO MUTUAL INTERDEPENDENCIES BETWEEN RHEUMATIC AND MUSCULOSKELETAL DISEASES AND MALIGNANCIES

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1248.2-1248
Author(s):  
K. Benesova ◽  
L. Diekmann ◽  
M. Czaja ◽  
K. Jordan ◽  
J. Leipe ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Clinical Management ◽  
Molecular Mechanisms ◽  
Musculoskeletal Diseases ◽  
Reference Population ◽  
University Hospital ◽  
Specific Situation ◽  
Research Support ◽  
Scientific Support ◽  
Gender Specific

Background:Knowledge about interdependencies between rheumatic and musculoskeletal diseases (RMDs) and malignancies is limited on the clinical and molecular level. Particularly, valid prospective data on the timely association of malignancies in patients with RMDs and treatment of the latter are sparse.Objectives:Due to the heterogeneous patient population, a registry-based study has been conducted in order to provide insights into mutual interdependencies and novel evidence for suitable clinical management of patients with concomitant RMD and malignancies.Methods:The RheuMal registry is a long-term, open-end observational study designed to address the specific situation of patients suffering from concomitant RMD and concomitant malignancy and/or premalignant conditions. The RheuMal registry is one of the three subregistries of the MalheuR project, a registry-based study initiated in July 2018 at the at the university hospital Heidelberg, Germany.Results:Data from the RheuMal registry (n=404) show an earlier onset of gender-specific cancers and malignant melanoma in RMD patients compared to data from the German Cancer Registry Data of the Robert-Koch-Institute: compared to the reference population, in RMD patients breast cancer (n=32) occurred 5.3 years and prostate cancer (n=16) 3.3 years earlier. Onset of malignant melanoma was 2.4 years earlier in females (n=9) and 1.1 years in males (n=7) with concomitant RMD. The mean latency between the initial diagnosis of the RMD and the later occurring malignant condition was 10.2 years. The diagnosis of the malignancy frequently led to a change or interruption of disease-modifying antirheumatic therapy in RMDs.Conclusion:The RheuMal registry offers first insights into interdependencies between RMDs and malignancies based on demographic data, disease characteristics, clinical management and outcome as well as correlation of specific diagnoses and therapies. The earlier onset of gender-specific cancers and malignant melanoma suggests differences in the epidemiology and course of the malignant disease in RMD patients compared to a healthy reference population, suggesting interdependency between the two disease entities. Future research will focus on further understanding of this interdependency und the underlying molecular mechanisms.Disclosure of Interests:Karolina Benesova Grant/research support from: Study grants for SCREENED study by Abbvie, Novartis and Rheumaliga Baden-Württemberg, Consultant of: One-time participation in Novartis advisory board., Leonore Diekmann: None declared, Maria Czaja: None declared, Karin Jordan Consultant of: Consultancy and/or speaker fees: MSD, Merck, Amgen, Hexal, Riemser, Helsinn, Tesaro, Kreussler, Voluntis, Pfizer, Pomme-med., Jan Leipe Grant/research support from: Consultancy and speaker fees: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Scientific support: Novartis, Pfizer., Consultant of: Consultancy and speaker fees: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Scientific support: Novartis, Pfizer., Speakers bureau: Abbvie, AstraZeneca, BMS, Celgene, Hospira, Janssen-Cilag, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Hanns-Martin Lorenz Grant/research support from: Consultancy and/or speaker fees and/or travel reimbursements: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly. Scientific support and/or educational seminars and/or clinical studies: Abbvie, MSD, BMS, Pfizer, Celgene, Medac, GSK, Roche, Chugai, Novartis, UCB, Janssen-Cilag, Astra-Zeneca, Lilly, Baxter, SOBI, Biogen, Actelion, Bayer Vital, Shire, Octapharm, Sanofi, Hexal, Mundipharm, Thermo Fisher., Consultant of: see above

scholarly journals Comparative Analysis of Main Clinical Features and Survival in Patients with Cutaneous Malignant Melanoma with and without Sentinel Lymph Node Biopsy

2020 ◽  
Author(s):  
Strashilov Strahil ◽  
Joana Ivanova Simeonova ◽  
Assia Andrianova Konsoulova ◽  
Mariela Borisova Vasileva-Slaveva ◽  
Angel Dancev Yordanov
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Sentinel Lymph Node Biopsy ◽  
Malignant Melanoma ◽  
Lymph Node Biopsy ◽  
Cutaneous Malignant Melanoma ◽  
University Hospital ◽  
Node Biopsy ◽  
Significant Difference ◽  
Group A

Abstract Background Sentinel lymph node biopsy is fundamental in the treatment and prognosis of cutaneous malignant melanoma. The aim of this study is to identify differences in baseline clinical characteristics and survival of patients with melanoma with and without sentinel lymph node biopsy (SLNB) performed. Methods In 2018, a retrospective study of 151 patients with malignant melanoma (MM) was conducted. The patients were hospitalized at the Second Clinic of University Hospital – Pleven, for the period 2012 to 2017. The patients were divided into two groups: Group A included 58 (38.4%) patients with SLNB performed; Group B included 93 (61.6%) patients who did not undergo SLNB. A double-detection method was used while performing SLNB. Results The incidence of achromatic malignant melanoma is significantly higher in patients without SLNB performed (12 or 12.9%), than in patients with SLNB performed (2 or 3.4%) – χ2 = 3.796, df = 1, p = 0.051. Of all 151 patients in the study, 46 died, representing 30.5 per 100 patients with melanoma. Mortality rate is higher in patients without SLNB (32.3% versus 27.6% in Group A). However, the differences in the two groups are not statistically significant. Conclusions Patients with achromatic melanoma have significantly fewer SLN biopsies performed because of a late diagnosis. Most of our patients are diagnosed at a later stage when lymphatic metastases are already present which leads to a significant increase in lymph node dissections performed. There is no significant difference in mortality and survival in the SLNB and non-SLNB groups.

scholarly journals Artificial Skin INTEGRA Use in the Treatment of Large Melanocytic Nevi

2020 ◽  
Vol 19 (1-2) ◽  
pp. 62-70
Author(s):  
Dainius Geležauskas ◽  
Rūta Dubosaitė
Keyword(s):  
Malignant Melanoma ◽  
University Hospital ◽  
Artificial Skin ◽  
Skin Substitute ◽  
Radical Excision ◽  
Melanocytic Nevi ◽  
Malignant Skin ◽  
Risk Of Malignancy ◽  
Vilnius University ◽  
Congenital Melanocytic Nevi

Melanocytic nevi are congenital, benign, pigmented proliferations. They have high risk of malignancy, most frequently transform to malignant skin melanoma and 70% it occurs in the first life decade. The risk of malignant transformation increases proportionately to their size. The best way to avoid those risks is early and radical excision. In 1996 on the market appeared the Integra™ artificial skin, has made it possible to improve the methods for the elimination of large congenital nevi and significantly reduce the risk of malignant melanoma, at an early age. 2011–2019, in Children’s Hospital, Affiliate of Vilnius University Hospital Santaros Clinics, the Integra™ was used to treat congenital melanocytic nevi in four children. Implantation of the skin substitute Integra™ has been successful for all the patients, the prognosis was good. The treatment of congenital melanocytic nevi is a necessity to avoid the risk of developing malignant melanoma. The rarity of this condition has led to the fact that so far there is no universal approach for all the cases. Integra™ artificial skin is an excellent choice for the treatment of congenital melanocytic nevi, especially for paediatric patients.

Sign in / Sign up

Export Citation Format

Share Document